Showing results (521-530 of 1,376) with videos related to

Sort By:
Pageof 138
Neuro-Oncology Advances|March 16, 2023
Corrigendum to: Leveraging the CSF proteome toward minimally-invasive diagnostics surveillance of brain malignancies
Neuro-Oncology Advances|August 30, 2021
Parents' experiences of postmortem tumor donation for high-grade gliomas: benefits and suggested improvementsEden G Robertson, Claire E Wakefield, Maria Tsoli, et al.
Neuro-Oncology Advances|February 8, 2023
Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastomaAndrea Schmidts, Ambike A Srivastava, Rishab Ramapriyan, et al.
Neuro-Oncology Advances|February 15, 2023
Collagen deposition within brain metastases is associated with leptomeningeal failure after cavity-directed radiosurgeryMohammed Abdulhaleem, Jimmy Ruiz, Stacey O'Neill, et al.
Neuro-Oncology Advances|February 23, 2023
Discovery of clinical and demographic determinants of symptom burden in primary brain tumor patients using network analysis and unsupervised clusteringBrandon H Bergsneider, Elizabeth Vera, Ophir Gal, et al.
Neuro-Oncology Advances|February 16, 2026
Beyond proof-of-concept: Validating robust automated diffuse lower-grade glioma segmentation for clinical applications in longitudinal follow-upJeremy Deverdun, Guillaume Clain, Margaux Verdier, et al.
Neuro-Oncology Advances|February 16, 2026
Evaluation of sex differences in survival among glioblastoma patients treated with immune checkpoint inhibitorsVihang Nakhate, Catharina Westergaard, Zhou Lan, et al.
Neuro-Oncology Advances|February 12, 2026
Pre-treatment journey and outcome for children with intracranial non-germinomatous germ cell tumors-the Shanghai experienceAnan Zhang, Xiang Huang, Yijin Gao, et al.
Neuro-Oncology Advances|March 5, 2025
Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatmentAmélie Darlix, Pierre Bady, Jérémy Deverdun, et al.
Neuro-Oncology Advances|March 7, 2025
Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survivalEduardo Rodriguez Almaraz, Geno A Guerra, Nadeem N Al-Adli, et al.
Pageof 138